❌

Normal view

  • ✇MIT Technology Review
  • Google’s new AI will help researchers understand how our genes work Antonio Regalado
    When scientists first sequenced the human genome in 2003, they revealed the full set of DNA instructions that make a person. But we still didn’t know what all those 3 billion genetic letters actually do.  Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that predicts what effects small changes in DNA will have on an array of molecular processes, such as whether a gene’s activity will go up or down. It’s just the sort of questi
     

Google’s new AI will help researchers understand how our genes work

25 June 2025 at 22:00

When scientists first sequenced the human genome in 2003, they revealed the full set of DNA instructions that make a person. But we still didn’t know what all those 3 billion genetic letters actually do. 

Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that predicts what effects small changes in DNA will have on an array of molecular processes, such as whether a gene’s activity will go up or down. It’s just the sort of question biologists regularly assess in lab experiments.

“We have, for the first time, created a single model that unifies many different challenges that come with understanding the genome,” says Pushmeet Kohli, a vice president for research at DeepMind.

Five years ago, the Google AI division released AlphaFold, a technology for predicting the 3D shape of proteins. That work was honored with a Nobel Prize last year and spawned a drug-discovery spinout, Isomorphic Labs, and a boom of companies that hope AI will be able to propose new drugs.

AlphaGenome is an attempt to further smooth biologists’ work by answering basic questions about how changing DNA letters alters gene activity and, eventually, how genetic mutations affect our health. 

“We have these 3 billion letters of DNA that make up a human genome, but every person is slightly different, and we don’t fully understand what those differences do,” says Caleb Lareau, a computational biologist at Memorial Sloan Kettering Cancer Center who has had early access to AlphaGenome. “This is the most powerful tool to date to model that.”

Google says AlphaGenome will be free for noncommercial users and plans to release full details of the model in the future. According to Kohli, the company is exploring ways to “enable use of this model by commercial entities” such as biotech companies. 

Lareau says AlphaGenome will allow certain types of experiments now done in the lab to be carried out virtually, on a computer. For instance, studies of people who’ve donated their DNA for research often turn up thousands of genetic differences, each slightly raising or lowering the chance a person gets a disease such as Alzheimer’s.

Lareau says DeepMind’s software could be used to quickly make predictions about how each of those variants works at a molecular level, something that would otherwise require time-consuming lab experiments. “You’ll get this list of gene variants, but then I want to understand which of those are actually doing something, and where can I intervene,” he says. “This system pushes us closer to a good first guess about what any variant will be doing when we observe it in a human.”

Don’t expect AlphaGenome to predict very much about individual people, however. It offers clues to nitty-gritty molecular details of gene activity, not 23andMe-type revelations of a person’s traits or ancestry. 

“We haven’t designed or validated AlphaGenome for personal genome prediction, a known challenge for AI models,” Google said in a statement.

Underlying the AI system is the so-called transformer architecture invented at Google that also powers large language models like GPT-4. This one was trained on troves of experimental data produced by public scientific projects.

Lareau says the system will not broadly change how his lab works day to day but could permit new types of research. For instance, sometimes doctors encounter patients with ultra-rare cancers, bristling with unfamiliar mutations. AlphaGenome could suggest which of those mutations are really causing the root problem, possibly pointing to a treatment.

“A hallmark of cancer is that specific mutations in DNA make the wrong genes express in the wrong context,” says Julien Gagneur, a professor of computational medicine at the Technical University of Munich. “This type of tool is instrumental in narrowing down which ones mess up proper gene expression.” 

The same approach could apply to patients with rare genetic disease, many of whom never learn the source of their condition, even if their DNA has been decoded. “We can obtain their genomes, but we are clueless as to which genetic alterations cause the disease,” says Gagneur. He thinks AlphaGenome could give medical scientists a new way to diagnose such cases. 

Eventually, some researchers aspire to use AI to design entire genomes from the ground up and create new life forms. Others think the models will be used to create a fully virtual laboratory for drug studies. “My dream would be to simulate a virtual cell,” Demis Hassabis, CEO of Google DeepMind, said this year. 

Kohli calls AlphaGenome a “milestone” on the road to that kind of system. “AlphaGenome may not model the whole cell in its entirety … but it’s starting to sort of shed light on the broader semantics of DNA,” he says.

Rescuing dendritic cell interstitial motility sustains antitumour immunity

Nature, Published online: 25 June 2025; doi:10.1038/s41586-025-09202-9

Disruption of dendritic cell (DC) interstitial motility in the tumour microenvironment promotes immune evasion, and enhancement of DC interstitial motility offers a route for DC-centric immunotherapy.
  • ✇MRD
  • Clinical Utility of ctDNA Analysis in Lung Cancer-A Review Kamil Makar · Agata Wróbel · Adam Antczak · Damian Tworek
    Adv Respir Med. 2025 Jun 12;93(3):17. doi: 10.3390/arm93030017.ABSTRACTCirculating free DNA (cfDNA) is genetic material released from various cells into bodily fluids. Among its fractions, circulating tumor DNA (ctDNA) originates from tumor cells and reflects their genetic material, including mutations and epigenetic changes. Methods commonly employed for detecting ctDNA in blood include next-generation sequencing (NGS) and various types of PCR. The presence of ctDNA can be utilized in liquid bi
     

Clinical Utility of ctDNA Analysis in Lung Cancer-A Review

25 June 2025 at 18:00

Adv Respir Med. 2025 Jun 12;93(3):17. doi: 10.3390/arm93030017.

ABSTRACT

Circulating free DNA (cfDNA) is genetic material released from various cells into bodily fluids. Among its fractions, circulating tumor DNA (ctDNA) originates from tumor cells and reflects their genetic material, including mutations and epigenetic changes. Methods commonly employed for detecting ctDNA in blood include next-generation sequencing (NGS) and various types of PCR. The presence of ctDNA can be utilized in liquid biopsies for many diagnostic purposes related to various cancers. It is a minimally invasive method of sampling molecular compounds from tumor cells. In this paper, we focus on current knowledge regarding the liquid biopsy of blood ctDNA in the context of lung cancer, one of the leading causes of cancer-related mortality. Currently, as a clinically approved method, liquid biopsy serves as a complementary technique in NSCLC diagnostic and genetic profiling. Other applications of liquid biopsy that are still being investigated include the detection of minimal residual disease (MRD) after curative treatment and response monitoring to systemic treatment. This review discusses current and future potential directions for the development and implementation of ctDNA for patients with NSCLC.

PMID:40558116 | PMC:PMC12189613 | DOI:10.3390/arm93030017

MiniMax Releases M1: a 456B Hybrid-Attention Model for Long-Context Reasoning and Software Tasks

25 June 2025 at 02:55

MiniMax has introduced MiniMax-M1, a new open-weight reasoning model built to handle extended contexts and complex problem-solving with high efficiency. Built on top of the earlier MiniMax-Text-01, M1 features a hybrid Mixture-of-Experts (MoE) architecture and a novel “lightning attention” mechanism.

By Robert Krzaczyński

Midjourney Debuts V1 AI Video Model

24 June 2025 at 18:31

Midjourney has launched its first video generation V1 model, a web-based tool that allows users to animate still images into 5-second video clips.

By Daniel Dominguez

Gastric cancer: from biomarkers to functional precision medicine

Trends Mol Med. 2025 Jun 23:S1471-4914(25)00118-2. doi: 10.1016/j.molmed.2025.05.007. Online ahead of print.

ABSTRACT

Gastric cancer (GC) remains a deadly disease because of late detection and limited treatment options at advanced stages. Treatment of patients with metastatic disease is based on chemotherapy, complemented by antibodies targeting HER2, VEGFR2, and more recently PD-1 or claudin 18.2. Further targets, such as FGFR2b, as well as novel drug classes including antibody-drug conjugates (ADCs) and bispecific antibodies, are promising developments in GC treatment. Despite the failure of several targeted agents, the landscape of GC therapy is evolving rapidly, facilitated by umbrella or platform precision medicine trials. The integration of next-generation sequencing and other omics techniques into molecular tumor boards, as well as functional drug testing on patient-derived models, might bring us closer to personalized oncology and ultimately improve patient survival.

PMID:40555635 | DOI:10.1016/j.molmed.2025.05.007

Integrative Multi-Omic and Immune Profiling of Lung Adenocarcinoma: Molecular Landscapes, Gene Expression, and Treatment Response Insights

Oncologist. 2025 Jun 24:oyaf191. doi: 10.1093/oncolo/oyaf191. Online ahead of print.

ABSTRACT

BACKGROUND: Lung adenocarcinoma (LUAD) is a major cause of cancer death. Traditional histopathological classification overlooks molecular heterogeneity, limiting personalized treatment. This study used multiomic data to define LUAD subtypes, assess prognostic significance, and analyze immune features, aiming to improve targeted therapy and clinical outcomes.

METHODS: This study used Consensus Clustering and Gap Statistics to analyze LUAD multiomic data, including mRNA, lncRNA, miRNA, DNA methylation, and mutations. Clustering was validated by silhouette plots and heatmaps. Molecular characterization involved regulon activity, immune and metabolic profiling. Functional assays (qPCR, WB, CCK-8, flow cytometry) assessed NDNF's role in LUAD.

RESULTS: Two molecular LUAD subtypes showed distinct clustering and survival outcomes. One subtype had worse prognosis and unique immune features, including checkpoint expression and microenvironment differences. Gene signatures and metabolism varied by subtype. NDNF was downregulated in tumors; its overexpression suppressed LUAD cell viability and promoted apoptosis, suggesting tumor-suppressive function.

CONCLUSION: This study identifies two LUAD subtypes with distinct molecular and immune features linked to prognosis and therapy response. NDNF downregulation and its tumor-suppressive effects highlight its therapeutic potential. These findings support improved LUAD stratification and personalized treatment strategies.

IMPLICATIONS FOR PRACTICE: This study reveals two LUAD molecular subtypes with distinct prognoses and immune features, offering a basis for more precise treatment strategies. The identification of NDNF as a potential tumor suppressor suggests its value as both a biomarker and therapeutic target. These findings support improved LUAD stratification and personalized therapy.

PMID:40554675 | DOI:10.1093/oncolo/oyaf191

Unraveling the role of GPCR signaling in metabolic reprogramming and immune microenvironment of lung adenocarcinoma: a multi-omics study with experimental validation

Front Immunol. 2025 Jun 6;16:1606125. doi: 10.3389/fimmu.2025.1606125. eCollection 2025.

ABSTRACT

BACKGROUND: Lung adenocarcinoma (LUAD) is characterized by metabolic and immune heterogeneity, driving tumor progression and therapy resistance. While G protein-coupled receptors (GPCR) signaling is known to regulate metabolism and immunity in cancers, its role in LUAD remains poorly defined. This study explores the influence of GPCR signaling on LUAD metabolism and immune landscape.

METHODS: We performed non-negative matrix factorization (NMF) clustering of GPCR signaling genes in TCGA-LUAD cohort to identify distinct molecular subgroups. A prognostic model was developed based on GPCR signaling genes using least absolute shrinkage and selection operator (LASSO) analysis and Cox regression. Differentially expressed genes were analyzed for metabolic pathway enrichment and immune infiltration. In addition, key genes within GPCR signaling were identified and validated through functional assays.

RESULTS: NMF clustering based on GPCR signaling identified three subgroups in LUAD, with cluster 3 exhibiting poorer overall survival and significant enrichment in multiple prognostic associated metabolism pathways including purine, pyrimidine, glyoxylate and dicarboxylate metabolism. Then, we developed a GPCRscore prognostic model and validated across multiple cohorts, which effectively stratified LUAD patients into distinct risk groups. High-risk LUAD patients had an immunosuppressive microenvironment and activated metabolic reprogramming. ADM was identified as a key gene in the high-risk group, correlating with tumor stage, immune suppression, and resistance to immunotherapy. Clinically, ADM was highly expressed in tumor tissues and shows elevated concentrations in the peripheral blood of patients with advanced-stage LUAD. Subsequently, we demonstrated that knock-down of ADM in LUAD cells impaired their proliferation, migration, and invasion, while also reducing the angiogenic potential of endothelial cells in vitro. Adrenomedullin promoted LUAD progression in a murine metastasis model. Further, adrenomedullin inhibited CD8+ T cells proliferation, induced exhaustion, and impaired cytotoxic function. Finally, drug sensitivity and cell viability analysis showed LUAD patients with high levels of ADM exhibited sensitivity to the treatment of Staurosporine and Dasatinib.

CONCLUSIONS: In summary, this study reveals the pivotal role of GPCR signaling particularly mediated by ADM in orchestrating metabolic reprogramming and immune modulation in LUAD. ADM emerges as a potential predictive biomarker and therapeutic target, offering valuable implications for optimizing strategies.

PMID:40547013 | PMC:PMC12179119 | DOI:10.3389/fimmu.2025.1606125

  • ✇MIT Technology Review
  • More news from the labs of MIT MIT Alumni News Staff
    Hundred-year storm tides could strike every decade in Bangladesh Tropical cyclones can generate devastating storm tides—seawater heightened by the tides that causes catastrophic floods in coastal regions. An MIT study finds that as the planet warms, the recurrence of destructive storm tides will increase tenfold for one of the world’s hardest-hit regions. New electronic “skin” could lead to lightweight night-vision glasses  MIT engineers have developed a technique to grow and peel ultra
     

More news from the labs of MIT


Hundred-year storm tides could strike every decade in Bangladesh

Tropical cyclones can generate devastating storm tides—seawater heightened by the tides that causes catastrophic floods in coastal regions. An MIT study finds that as the planet warms, the recurrence of destructive storm tides will increase tenfold for one of the world’s hardest-hit regions.

New electronic “skin” could lead to lightweight night-vision glasses 

MIT engineers have developed a technique to grow and peel ultrathin “skins” of electronic material that could be used in wearable sensors, flexible transistors and computing elements, and sensitive compact imaging devices.

Technology makes pesticides stick to plant leaves

A new pesticide application system developed by MIT researchers and their spinoff company could significantly cut use of pesticides and fertilizers, saving farmers money and reducing polluting runoff.

New printable metamaterials that are both strong and stretchy could allow fabrication of bendable ceramics, glass, and metals.

These tough yet bendy materials could be made into tear-resistant textiles, flexible semiconductors, electronic chip packaging, and durable yet compliant scaffolds on which to grow cells for tissue repair.

  • ✇MIT Technology Review
  • Cancer-targeting nanoparticles are moving closer to human trials Anne Trafton
    Over the past decade, Institute Professor Paula Hammond ’84, PhD ’93, and her students have used a technique known as layer-by-layer assembly to create a variety of polymer-coated nanoparticles that can be loaded with cancer-fighting drugs. The particles, which could prevent many side effects of chemotherapy by targeting tumors directly, have proved effective in mouse studies. Now the researchers have come up with a technique that allows them to manufacture many more particles in much less time,
     

Cancer-targeting nanoparticles are moving closer to human trials

25 June 2025 at 05:00

Over the past decade, Institute Professor Paula Hammond ’84, PhD ’93, and her students have used a technique known as layer-by-layer assembly to create a variety of polymer-coated nanoparticles that can be loaded with cancer-fighting drugs. The particles, which could prevent many side effects of chemotherapy by targeting tumors directly, have proved effective in mouse studies. Now the researchers have come up with a technique that allows them to manufacture many more particles in much less time, moving them closer to human use.

“There’s a lot of promise with the nanoparticle systems we’ve been developing, and we’ve been really excited more recently with the successes that we’ve been seeing in animal models for our treatments for ovarian cancer in particular,” says Hammond, the senior author of a paper on the new technique along with Darrell Irvine, a professor at the Scripps Research Institute.

In the original production technique, layers with different properties can be laid down by alternately exposing a particle to positively and negatively charged polymers, with extensive purification to remove excess polymer after each application. Each layer can carry therapeutics as well as molecules that help the particles find and enter cancer cells. But the process is time-consuming and would be difficult to scale up. 

In the new work, the researchers used a microfluidic mixing device that allows them to sequentially add layers as the particles flow through a microchannel. For each layer, they can calculate exactly how much polymer is needed, which eliminates the slow and costly purification step and saves significantly on material costs.

gloved hands hold the device
This microfluidic device can be used to assemble the drug delivery nanoparticles rapidly and in large quantities.
GRETCHEN ERTL

This strategy also facilitates compliance with the FDA’s GMP (good manufacturing practice) requirements, which ensure that products meet safety standards and can be manufactured consistently. “There’s much less chance of any sort of operator mistake or mishaps,” says Ivan Pires, PhD ’24, a postdoc at Brigham and Women’s Hospital and a visiting scientist at the Koch Institute, who is the paper’s lead author along with Ezra Gordon ’24. “We can create an innovation within the layer-by-layer nanoparticles and quickly produce it in a manner that we could go into clinical trials with.”

In minutes, the researchers can generate 15 milligrams of nanoparticles (enough for about 50 doses for certain cargos), which would have taken close to an hour with the original process. They say this means it would be realistic to produce more than enough for clinical trials and patient use.

To demonstrate the technique, the researchers created layered nanoparticles loaded with the immune molecule ­interleukin-­12; they have previously shown that such particles can slow growth of ovarian tumors in mice. Those manufactured using the new technique performed similarly to the originals and managed to bind to cancer tissue without entering the cancer cells. This lets them serve as markers that activate the immune system in the tumor, which can delay tumor growth and even lead to cures in mouse models of ovarian cancer. 

The researchers have filed for a patent and are working with MIT’s Deshpande Center for Technological Innovation in hopes of forming a company to commercialize the technology, which they say could also be applied to glioblastoma and other types of cancer. 

  • ✇InfoQ
  • New Crypto-Jacking Attacks Target DevOps and AI Infrastructure Matt Saunders
    Security researchers at Wiz have uncovered a sophisticated crypto-jacking attack targeting publically accessible API servers for several popular DevOps tools. Similarly, researchers at Sysdig have uncovered an attack on the popular AI tool Open WebUI using many of the same techniques and crypto-miners. By Matt Saunders
     

New Crypto-Jacking Attacks Target DevOps and AI Infrastructure

24 June 2025 at 16:00

Security researchers at Wiz have uncovered a sophisticated crypto-jacking attack targeting publically accessible API servers for several popular DevOps tools. Similarly, researchers at Sysdig have uncovered an attack on the popular AI tool Open WebUI using many of the same techniques and crypto-miners.

By Matt Saunders
  • ✇MIT Technology Review
  • A Chinese firm has just launched a constantly changing set of AI benchmarks Caiwei Chen
    When testing an AI model, it’s hard to tell if it is reasoning or just regurgitating answers from its training data. Xbench, a new benchmark developed by the Chinese venture capital firm HSG, or HongShan Capital Group, might help to sidestep that issue. That’s thanks to the way it evaluates models not only on the ability to pass arbitrary tests, like most other benchmarks, but also on the ability to execute real-world tasks, which is more unusual. It will be updated on a regular basis to try to
     

A Chinese firm has just launched a constantly changing set of AI benchmarks

23 June 2025 at 23:46

When testing an AI model, it’s hard to tell if it is reasoning or just regurgitating answers from its training data. Xbench, a new benchmark developed by the Chinese venture capital firm HSG, or HongShan Capital Group, might help to sidestep that issue. That’s thanks to the way it evaluates models not only on the ability to pass arbitrary tests, like most other benchmarks, but also on the ability to execute real-world tasks, which is more unusual. It will be updated on a regular basis to try to keep it evergreen. 

This week the company is making part of its question set open-source and letting anyone use for free. The team has also released a leaderboard comparing how mainstream AI models stack up when tested on Xbench. (ChatGPT o3 ranked first across all categories, though ByteDance’s Doubao, Gemini 2.5 Pro, and Grok all still did pretty well, as did Claude Sonnet.) 

Development of the benchmark at HongShan began in 2022, following ChatGPT’s breakout success, as an internal tool for assessing which models are worth investing in. Since then, led by partner Gong Yuan, the team has steadily expanded the system, bringing in outside researchers and professionals to help refine it. As the project grew more sophisticated, they decided to release it to the public.

Xbench approached the problem with two different systems. One is similar to traditional benchmarking: an academic test that gauges a model’s aptitude on various subjects. The other is more like a technical interview round for a job, assessing how much real-world economic value a model might deliver.

Xbench’s methods for assessing raw intelligence currently include two components: Xbench-ScienceQA and Xbench-DeepResearch. ScienceQA isn’t a radical departure from existing postgraduate-level STEM benchmarks like GPQA and SuperGPQA. It includes questions spanning fields from biochemistry to orbital mechanics, drafted by graduate students and double-checked by professors. Scoring rewards not only the right answer but also the reasoning chain that leads to it.

DeepResearch, by contrast, focuses on a model’s ability to navigate the Chinese-language web. Ten subject-matter experts created 100 questions in music, history, finance, and literature—questions that can’t just be googled but require significant research to answer. Scoring favors breadth of sources, factual consistency, and a model’s willingness to admit when there isn’t enough data. A question in the publicized collection is “How many Chinese cities in the three northwestern provinces border a foreign country?” (It’s 12, and only 33% of models tested got it right, if you are wondering.)

On the company’s website, the researchers said they want to add more dimensions to the test—for example, aspects like how creative a model is in its problem solving, how collaborative it is when working with other models, and how reliable it is.

The team has committed to updating the test questions once a quarter and to maintain a half-public, half-private data set.

To assess models’ real-world readiness, the team worked with experts to develop tasks modeled on actual workflows, initially in recruitment and marketing. For example, one task asks a model to source five qualified battery engineer candidates and justify each pick. Another asks it to match advertisers with appropriate short-video creators from a pool of over 800 influencers.

The website also teases upcoming categories, including finance, legal, accounting, and design. The question sets for these categories have not yet been open-sourced.

ChatGPT-o3 again ranks first in both of the current professional categories. For recruiting, Perplexity Search and Claude 3.5 Sonnet take second and third place, respectively. For marketing, Claude, Grok, and Gemini all perform well.

“It is really difficult for benchmarks to include things that are so hard to quantify,” says Zihan Zheng, the lead researcher on a new benchmark called LiveCodeBench Pro and a student at NYU. “But Xbench represents a promising start.”

  • ✇MIT Technology Review
  • Book review: Surveillance & privacy Bryan Gardiner
    Privacy only matters to those with something to hide. So goes one of the more inane and disingenuous justifications for mass government and corporate surveillance. There are others, of course, but the “nothing to hide” argument remains a popular way to rationalize or excuse what’s become standard practice in our digital age: the widespread and invasive collection of vast amounts of personal data. One common response to this line of reasoning is that everyone, in fact, has something to hide, w
     

Book review: Surveillance & privacy

23 June 2025 at 18:00

Privacy only matters to those with something to hide. So goes one of the more inane and disingenuous justifications for mass government and corporate surveillance. There are others, of course, but the “nothing to hide” argument remains a popular way to rationalize or excuse what’s become standard practice in our digital age: the widespread and invasive collection of vast amounts of personal data.

One common response to this line of reasoning is that everyone, in fact, has something to hide, whether they realize it or not. If you’re unsure of whether this holds true for you, I encourage you to read Means of Control by Byron Tau. 

cover of Means of Control
Means of Control: How the Hidden Alliance of Tech and Government Is Creating a New American Surveillance State
Byron Tau
CROWN, 2024

Midway through his book, Tau, an investigative journalist, recalls meeting with a disgruntled former employee of a data broker—a shady company that collects, bundles, and sells your personal data to other (often shadier) third parties, including the government. This ex-employee had managed to make off with several gigabytes of location data representing the precise movements of tens of thousands of people over the course of a few weeks. “What could I learn with this [data]—­theoretically?” Tau asks the former employee. The answer includes a laundry list of possibilities that I suspect would make even the most enthusiastic oversharer uncomfortable.

“If information is power, and America is a society that’s still interested in the guarantee of liberty, personal dignity, and the individual freedom of its citizens, a serious conversation is needed.”

Bryon Tau, author of Means of Control

Did someone in this group recently visit an abortion clinic? That would be easy to figure out, says the ex-employee. Anyone attend an AA meeting or check into inpatient drug rehab? Again, pretty simple to discern. Is someone being treated for erectile dysfunction at a sexual health clinic? If so, that would probably be gleanable from the data too. Tau never opts to go down that road, but as Means of Control makes very clear, others certainly have done so and will.

While most of us are at least vaguely aware that our phones and apps are a vector for data collection and tracking, both the way in which this is accomplished and the extent to which it happens often remain murky. Purposely so, argues Tau. In fact, one of the great myths Means of Control takes aim at is the very idea that what we do with our devices can ever truly be anonymized. Each of us has habits and routines that are completely unique, he says, and if an advertiser knows you only as an alphanumeric string provided by your phone as you move about the world, and not by your real name, that still offers you virtually no real privacy protection. (You’ll perhaps not be surprised to learn that such “anonymized ad IDs” are relatively easy to crack.)

“I’m here to tell you if you’ve ever been on a dating app that wanted your location, or if you ever granted a weather app permission to know where you are 24/7, there’s a good chance a detailed log of your precise movement patterns has been vacuumed up and saved in some data bank somewhere that tens of thousands of total strangers have access to,” writes Tau.

Unraveling the story of how these strangers—everyone from government intelligence agents and local law enforcement officers to private investigators and employees of ad tech companies—gained access to our personal information is the ambitious task Tau sets for himself, and he begins where you might expect: the immediate aftermath of 9/11.

At no other point in US history was the government’s appetite for data more voracious than in the days after the attacks, says Tau. It was a hunger that just so happened to coincide with the advent of new technologies, devices, and platforms that excelled at harvesting and serving up personal information that had zero legal privacy protections. 

Over the course of 22 chapters, Tau gives readers a rare glimpse inside the shadowy industry, “built by corporate America and blessed by government lawyers,” that emerged in the years and decades following the 9/11 attacks. In the hands of a less skilled reporter, this labyrinthine world of shell companies, data vendors, and intelligence agencies could easily become overwhelming or incomprehensible. But Tau goes to great lengths to connect dots and plots, explaining how a perfect storm of business motivations, technological breakthroughs, government paranoia, and lax or nonexistent privacy laws combined to produce the “digital panopticon” we are all now living in.

Means of Control doesn’t offer much comfort or reassurance for privacy­-minded readers, but that’s arguably the point. As Tau notes repeatedly throughout his book, this now massive system of persistent and ubiquitous surveillance works only because the public is largely unaware of it. “If information is power, and America is a society that’s still interested in the guarantee of liberty, personal dignity, and the individual freedom of its citizens, a serious conversation is needed,” he writes. 

As another new book makes clear, this conversation also needs to include student data. Lindsay Weinberg’s Smart University: Student Surveillance in the Digital Age reveals how the motivations and interests of Big Tech are transforming higher education in ways that are increasingly detrimental to student privacy and, arguably, education as a whole.

cover of Smart University
Smart University: Student Surveillance in the Digital Age
Lindsay Weinberg
JOHNS HOPKINS UNIVERSITY PRESS, 2024

By “smart university,” Weinberg means the growing number of public universities across the country that are being restructured around “the production and capture of digital data.” Similar in vision and application to so-called “smart cities,” these big-data-pilled institutions are increasingly turning to technologies that can track students’ movements around campus, monitor how much time they spend on learning management systems, flag those who seem to need special “advising,” and “nudge” others toward specific courses and majors. “What makes these digital technologies so seductive to higher education administrators, in addition to promises of cost cutting, individualized student services, and improved school rankings, is the notion that the integration of digital technology on their campuses will position universities to keep pace with technological innovation,” Weinberg writes. 

Readers of Smart University will likely recognize a familiar logic at play here. Driving many of these academic tracking and data-gathering initiatives is a growing obsession with efficiency, productivity, and convenience. The result is a kind of Silicon Valley optimization mindset, but applied to higher education at scale. Get students in and out of university as fast as possible, minimize attrition, relentlessly track performance, and do it all under the guise of campus modernization and increased personalization. 

Under this emerging system, students are viewed less as self-empowered individuals and more as “consumers to be courted, future workers to be made employable for increasingly smart workplaces, sources of user-generated content for marketing and outreach, and resources to be mined for making campuses even smarter,” writes Weinberg. 

At the heart of Smart University seems to be a relatively straightforward question: What is an education for? Although Weinberg doesn’t provide a direct answer, she shows that how a university (or society) decides to answer that question can have profound impacts on how it treats its students and teachers. Indeed, as the goal of education becomes less to produce well-rounded humans capable of thinking critically and more to produce “data subjects capable of being managed and who can fill roles in the digital economy,” it’s no wonder we’re increasingly turning to the dumb idea of smart universities to get the job done.  

If books like Means of Control and Smart University do an excellent job exposing the extent to which our privacy has been compromised, commodified, and weaponized (which they undoubtedly do), they can also start to feel a bit predictable in their final chapters. Familiar codas include calls for collective action, buttressed by a hopeful anecdote or two detailing previously successful pro-privacy wins; nods toward a bipartisan privacy bill in the works or other pieces of legislation that could potentially close some glaring surveillance loophole; and, most often, technical guides that explain how each of us, individually, might better secure or otherwise take control and “ownership” of our personal data.

The motivations behind these exhortations and privacy-centric how-to guides are understandable. After all, it’s natural for readers to want answers, advice, or at least some suggestion that things could be different—especially after reading about the growing list of degradations suffered under surveillance capitalism. But it doesn’t take a skeptic to start to wonder if they’re actually advancing the fight for privacy in the way that its advocates truly want.

For one thing, technology tends to move much faster than any one smartphone privacy guide or individual law could ever hope to keep up with. Similarly, framing rampant privacy abuses as a problem we each have to be responsible for addressing individually seems a lot like framing the plastic pollution crisis as something Americans could have somehow solved by recycling. It’s both a misdirection and a misunderstanding of the problem.     

It’s to his credit, then, that Lowry Pressly doesn’t include a “What is to be done” section at the end of The Right to Oblivion: Privacy and the Good Life. In lieu of offering up any concrete technical or political solutions, he simply reiterates an argument he has carefully and convincingly built over the course of his book: that privacy is important “not because it empowers us to exercise control over our information, but because it protects against the creation of such information in the first place.” 

cover of The Right to Oblivion
The Right to Oblivion: Privacy and the Good Life
Lowry Pressly
HARVARD UNIVERSITY PRESS, 2024

For Pressly, a Stanford instructor, the way we currently understand and value privacy has been tainted by what he calls “the ideology of information.” “This is the idea that information has a natural existence in human affairs,” he writes, “and that there are no aspects of human life which cannot be translated somehow into data.” This way of thinking not only leads to an impoverished sense of our own humanity—it also forces us into the conceptual trap of debating privacy’s value using a framework (control, consent, access) established by the companies whose business model is to exploit it.

The way out of this trap is to embrace what Pressly calls “oblivion,” a kind of state of unknowing, ambiguity, and potential—or, as he puts it, a realm “where there is no information or knowledge one way or the other.” While he understands that it’s impossible to fully escape a modern world intent on turning us into data subjects, Pressly’s book suggests we can and should support the idea that certain aspects of our (and others’) subjective interior lives can never be captured by information. Privacy is important because it helps to both protect and produce these ineffable parts of our lives, which in turn gives them a sense of dignity, depth, and the possibility for change and surprise. 

Reserving or cultivating a space for oblivion in our own lives means resisting the logic that drives much of the modern world. Our inclination to “join the conversation,” share our thoughts, and do whatever it is we do when we create and curate a personal brand has become so normalized that it’s practically invisible to us. According to Pressly, all that effort has only made our lives and relationships shallower, less meaningful, and less trusting.

Calls for putting our screens down and stepping away from the internet are certainly nothing new. And while The Right to Oblivion isn’t necessarily prescriptive about such things, Pressly does offer a beautiful and compelling vision of what can be gained when we retreat not just from the digital world but from the idea that we are somehow knowable to that world in any authentic or meaningful way. 

If all this sounds a bit philosophical, well, it is. But it would be a mistake to think of The Right to Oblivion as a mere thought exercise on privacy. Part of what makes the book so engaging and persuasive is the way in which Pressly combines a philosopher’s knack for uncovering hidden assumptions with a historian’s interest in and sensitivity to older (often abandoned) ways of thinking, and how they can often enlighten and inform modern problems.

Pressly isn’t against efforts to pass more robust privacy legislation, or even to learn how to better protect our devices against surveillance. His argument is that in order to guide such efforts, you have to both ask the right questions and frame the problem in a way that gives you and others the moral clarity and urgency to act. Your phone’s privacy settings are important, but so is understanding what you’re protecting when you change them. 

Bryan Gardiner is a writer based in Oakland, California. 

Integrated spatial omics of metabolic reprogramming and the tumor microenvironment in pancreatic cancer

iScience. 2025 May 15;28(6):112681. doi: 10.1016/j.isci.2025.112681. eCollection 2025 Jun 20.

ABSTRACT

Metabolic reprogramming is a defining feature of pancreatic cancer, influencing tumor progression and the tumor microenvironment. By integrating single-cell transcriptomics, spatial transcriptomics, and spatial metabolomics, this study visualized the spatial co-localization of metabolites and gene expression within tumor samples, uncovering metabolic heterogeneity and intercellular interactions. Spatial transcriptomics identified distinct pathological regions, which were further characterized using single-cell transcriptomic data and pathologist annotations. Pseudotime trajectory analysis revealed metabolic shifts along the malignant progression, while single-cell Metabolism (scMetabolism) delineated metabolic differences between pathological regions, classifying them as hypermetabolic or hypometabolic. Notably, aberrant cell communication between cancer cells, macrophages, and fibroblasts was observed, with key receptor-ligand pairs significantly co-expressed in malignant regions and correlated with poor prognosis. Spatial metabolomics imaging identified signature metabolites, highlighting metabolic alterations in amino acid metabolism, polyamine metabolism, fatty acid synthesis, and phospholipid metabolism. This integrated analysis provides critical insights into pancreatic cancer metabolism, offering potential avenues for targeted therapeutic interventions.

PMID:40538442 | PMC:PMC12177182 | DOI:10.1016/j.isci.2025.112681

Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications

Cancer Treat Rev. 2025 Jun 14;139:102979. doi: 10.1016/j.ctrv.2025.102979. Online ahead of print.

ABSTRACT

Breast cancer is characterized by significant molecular heterogeneity; therefore, there are distinct clinical features, treatment modalities, and prognostic outcomes across its various molecular subtypes. In the era of precision medicine, liquid biopsy has emerged as a convenient and minimally invasive technique capable of dynamically representing the comprehensive tumor gene spectrum. This review systematically elaborates the clinical value of liquid biopsy as a breakthrough tool for precision diagnosis and treatment in breast cancer through dynamic detection of key biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and non-coding RNA (ncRNA). Specific genetic mutations and methylation signatures in ctDNA can be applied to early breast cancer screening, minimal residual disease monitoring, and tracking drug resistance mechanisms. CTCs enumeration (≥1/7.5 mL in early-stage cancer or ≥ 5/7.5 mL in metastatic cancer) and PD-L1 expression levels demonstrate direct correlations with prognostic stratification and the efficacy of immunotherapy. As the specificity and sensitivity of liquid biopsy continue to improve, personalized treatment strategies, informed by biomarker analysis and targeted precision therapies, have unveiled new avenues of hope for patients with breast cancer. However, several challenges persist in the practical application of liquid biopsy. Despite persistent challenges, such as insufficient standardization and difficulties in resolving low-abundance variants, future advancements should focus on multi-omics integration and AI-driven technological breakthroughs to overcome bottlenecks in clinical translation. This review summarizes cutting-edge liquid biopsy technologies for identifying clinically significant molecular biomarkers, focusing on discussing critical challenges in the strategies to advance precision oncology applications for optimized treatment guidance and disease surveillance in breast cancer.

PMID:40540857 | DOI:10.1016/j.ctrv.2025.102979

Exploring AI tools and multi-omics for precision medicine in lung cancer therapy

Cytokine Growth Factor Rev. 2025 Jun 6:S1359-6101(25)00071-1. doi: 10.1016/j.cytogfr.2025.06.001. Online ahead of print.

ABSTRACT

Lung cancer is a leading cause of cancer-related mortality worldwide, characterized by the uncontrolled growth and spread of abnormal cells. Despite constant progress in diagnosis and treatment of lung cancer remains highly challenging. Present review explores the molecular underpinnings of lung cancer, emphasizing genetic mutations, altered metabolism, and the role of biomarkers in diagnosis and treatment. Advances in diagnostic methods, particularly liquid biopsies, have enabled non-invasive detection and monitoring of lung cancer. Therapeutic approaches have evolved significantly, with molecular-targeted therapies focusing on pathways like EGFR, ALK, KRAS, and MET. Caner Immunotherapy, including immune checkpoint inhibitors, artificial intelligence, and multi-omics analysis, including genomics and image data to predict treatment response, has further enhanced precision medicine by enabling earlier detection, better prognostic models, and efficient drug discovery. AI has a significant impact on various aspects of oncology, including improving the earlier diagnosis of lung cancer. Despite these advancements, challenges such as drug resistance, tumor heterogeneity, and limited efficacy of certain therapies persist, necessitating continued research and innovation.

PMID:40544104 | DOI:10.1016/j.cytogfr.2025.06.001

❌